hotspot -WSS

hotspot

author：focus 2025-09-03 03:42:31 - browse：5

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Bristol Myers buys into radiopharmaceuticals with RayzeBio

WSS

Patients, doctors press FTC to beef up hospital merger scrutiny

Why health records don't always know when patients are dead

Can sheer will power keep patients alive in their dying hours?

PBMs drew scrutiny in House hearing — and so did pharma

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Senate bill would ban some hospital facility fees

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Peter Hotez and the public health issue of online harassment

People with substance use disorder deserve online privacy

Alkermes shareholders re

People with substance use disorder deserve online privacy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Chamber of Commerce, DOJ clash in court over drug prices

Medical leaders decry Supreme Court decision on affirmative action

Grad students accuse University of California of wage theft

ChatGPT in medicine: STAT answers readers' burning questions

Midwives could help bridge maternal health disparities in the U.S.

Wikipedia

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Virtual care provider acquires bankrupt Pear's prescription apps

White House Covid adviser calls on docs to combat misinformation

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Drinking less cuts risk of oral cavity, esophageal cancer: Report

How the messy conversation about Dolly changed bioethics

leisure time

knowledge

hotspot

Wikipedia